$945 | Single User
$4725 | Site License
$14175 | Global License

Branded Generics in South East Asia: Current and Future Opportunities
[Lowest Price Guaranteed: $945]

Published by FirstWord Pharma: 01 Apr 2012 | 11 | In Stock
Related Topics: Business , Pharmaceuticals



With its fast-growing, young population and projected pharmaceutical sales in excess of billion in 2014, countries in the Association of South East Asian Nations (ASEAN) represent a great opportunity for Pharma.

However, with regional marketing practices, uncertain production values of locally manufactured generics and a huge diversity in healthcare delivery across ten nations of varying income levels, there are also great challenges.

Despite the disadvantages large multinationals face, major pharmaceutical companies are diving into the region, focusing on revenue from new chemical entities and developing ‘branded’ generics as key investments.

But given regional dynamics, pro-generic legislation, inconsistent IPR enforcement and local industry protection, what are the factors that the industry can leverage to drive success?


Report Overview

Based on interviews with ten of the region’s most experienced industry experts, Branded Generics in S.E. Asia: Current and Future Opportunities explores why the pharmaceutical industry is focusing on branded generics and new chemical entity (NCE) revenues. Timely and packed with essential details, the report describes the current state-of-play, the future of branded generics and the physician, prescriber and patient dynamics that govern drug dispensing.

By offering insight into the complex forces at work, this comprehensive report provides the critical intelligence necessary for success within the region. Can Big Pharma firmly insert itself into such a vibrant but locally-dominated market? Branded Generics in S.E. Asia: Current and Future Opportunities has the answers.


Key Report Features

  • Insight into why ASEAN markets are difficult for multinationals to penetrate

  • Timely, targeting information on regional dynamics

  • Discussion of ASEAN harmonization, how it is challenging regulatory and manufacturing standards and how that will impact local players

  • The role of government intervention, particularly in pro-generic legislation

  • The impact of local industry protection in creating barriers for multinationals

  • Strategies the industry is employing to take advantage of quality control legislation

  • Overview of regional economics

  • Puchase Reasons

    Who Would Benefit From This Report?

    This report will be of value to senior pharma directors and managers with responsibilities in the following areas:

  • Executive management

  • Licensing/Business development

  • Market research and business intelligence

  • Marketing, category and product management

  • Key account and territory management

  • Emerging market development

  • Regulatory and government affairs

  • Key Questions Answered

  • What are the main challenges facing Big Pharma in South East Asia?

  • How can multinationals effectively gain traction in ASEAN countries?

  • Who is best adapting to regional conditions and how is it being done?

  • What are the conditions favouring local producers?

  • Who are the key decision makers and what are the factors influencing them?

  • How can multinationals adapt to changing government regulation?

  • What is the net benefit of establishing relationships with local companies?

  • Key Benefits

  • Gain insight into the complexity of the ASEAN region

  • Deepen your understanding of the current market situation in South East Asia

  • Find out how pro-generic legislation, local industry protection and manufacturing weaknesses have resulted in a lack of regional leaders

  • Gain insight into why most—but not all—local companies won’t survive ASEAN harmonization

  • Find out how success will be dependent upon quickly adapting to new regulatory standards and marketing the right branded generics to suit regional demographics

  • Receive insight into major commercial opportunities

  • Key quotes

    “What’s important is where the power lies, so when the power lies with the doctor, we have a branded generics kind of a market. When the power lies with the payer, which could be the government, insurance scheme, wholesaler or the pharmacies, then it becomes a more or less an unbranded generics market.” – Manish Bajaj, Senior Director Strategy for Branded Generics Markets, Dr Reddy’s

    “At present the jury is still out. Companies have started launching their branded generic brands but I can't say for sure that success is guaranteed in South East Asia.” – Dr. Suchitra Kataria, former Head of Business Development and In-Licensing - Regional Strategic Development Asia Pacific at Bayer Schering Pharma, Singapore

    “If you really talk about success in terms of 20-25 years... the branded generics market will move to a more unbranded generics market as we have seen in Europe.” – Manish Bajaj, Senior Director Strategy for Branded Generics Markets, Dr Reddy’s

    Expert Views

  • Manish Bajaj, Senior Director Strategy for Branded Generics Markets, Dr Reddy’s, India.

  • Y.S. Chua, ex Business Development Director, Sanofi, Malaysia.

  • Peter Dolinsky, General Manager Medinova Asia, DKSH, Thailand.

  • Dean Edwards, ex VP, Sales, Asia Pacific, IMS Health and Founder Oliver Henry Consulting.

  • Andrew Howden, CEO iNova, Australia.

  • Jason Humphries, Managing Director, Good Pharmaceuticals, Singapore.

  • Dr. Suchitra Kataria, academic at the University of Wales, Singapore campus and previous Head Business Development and In-Licensing - Regional Strategic Development Asia Pacific at Bayer Schering Pharma, Singapore.

  • Peter Keil, VP & Regional Director Asia, Alvogen, Thailand.

  • Andrew Moore, VP Business Development, InnoBio Ventures, Malaysia.

  • Giles Moss, AFT Pharmaceuticals S.E. Asia, Malaysia.
  • Table of Contents
    for Branded Generics in South East Asia: Current and Future Opportunities

    • 1. Executive Summary

      2.South East Asia background

      2.1. The geography and population of the region

      2.2 The economics of the region

      2.3. Populations remain young but lifestyle changes are impacting treatment trends

      3.Defining ‘Branded Generics’

      3.1. Local market structures are complex

      3.2. Most promotion surrounds brands

      3.3. Local marketing practices put international companies at a disadvantage

      3.4. Background summary

      4.What is the situation in 2012

      4.1. Local companies dominate the market

      4.2. Robust growth in generic and branded generics is forecast

      4.3. Decision making starting to shift from physicians and pharmacists to patients

      4.4. A flight to quality is apparent

      5.Multinationals target the branded generic segment

      5.1. The situation in 2012

      6.Drivers of the move to marketing branded generics in South East Asia

      7.1. Slower growth globally

      7.2. ASEAN pharmaceutical harmonization drives quality

      7.3. No dominant regional players

      7.4. Physician and patient attitudes are changing

      7.5. Government intervention

      7.6. Pro generic legislation

      7.7. Inconsistent IP protection

      7.8. Local industry protection

      7.9. Indian market position tainted by quality issues

      7.10. Summary of the drivers of the move to marketing branded generics in South East Asia

      8.The impact of events in 2012 on the future

      8.1. Acquisition of brands to suit branded generic markets

      8.2.Regulatory strategy refinement

      8.3. Multinational - go to market strategy

      8.4. How will 2012 impact the future summary

      9.What are the decisive factors that will determine future success

      9.1. Taking advantage of new quality standards and IP enforcement

      9.2. Speed of local implementation

      9.3. Cultural adjustment within the big multinational companies

      9.4. Creating innovative win-win deals

      9.5. Maintaining flexibility for government intervention

      9.6. What will determine success summary


      11.Appendix 1

      11.1.ASEAN aims and purposes

      11.2.ASEAN fundamental principles

      12.Appendix 2


    Additional Details


    FirstWord Pharma

    Publisher Information


    11 |

    Number of Pages


    Report Format


    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Cephalosporin Market by Generation (First-generation, Second-generation, Third-generation, Fourth-generation, and Fifth-generation), Type (Branded and Generics), Route of Drug Administration (Injection and Oral), and Application (Respiratory Tract Infection, Skin Infection, Ear Infection, Urinary Tract Infection, and Sexually Transmitted Infection) - Global Opportunity Analysis and Industry Foreca
    Cephalosporin is a group of semisynthetic, broad-spectrum antibiotics, which is majorly used to trea...
    01 Nov 2017 by Allied Market Research USD $5,370 More Info
    Apple Accessories Market: Increasing Sales of iPhones Across the Globe Expected to Boost Demand for Apple Accessories and Apple Branded Accessories During the Forecast Period: Global Industry Analysis and Opportunity Assessment, 2016-2020
    Screen Guards to remain the most important product type segment for both iPhone and iPadModern day s...
    03 Apr 2017 by Future Market Insights USD $5,000 More Info
    Branded Generics Market: Oncology Therapeutic Application Segment Expected to Grow Significantly in Developed Markets over the Forecast Period: Global Industry Analysis & Opportunity Assessment, 2016 –2026
    Increasing prevalence of chronic and lifestyle diseases expected to create demand for branded generi...
    13 Jan 2017 by Future Market Insights USD $5,000 More Info
    Nutraceuticals Market by Type (Functional Food (Probiotics Fortified Foods, Omega Fatty Acid Fortified Food, Branded Ionized Salts, Branded Wheat Flour Market, and Other Functional Food), Functional Beverages (Fruits and Vegetable Juices & Drinks, Dairy & Dairy Alternative Drinks, Non-Carbonated Drinks (Bottled water, Tea, and Coffee, and Others (Herbal tea, Sports drinks, Energy drinks), Dietary
    Nutraceuticals market is expected to grow at a CAGR of 7.04% from 2016 to 2022 to reach 2,306 mil...
    25 Dec 2016 by Allied Market Research USD $5,370 More Info
    Automotive E-tailing Market by Vehicle Type, Vendor (OEM and Third Party), Product Label (Branded and Counterfeit), Components (Infotainment, Interior Accessories, Engine Components, Tires, and Electrical Products), Technology, and Region - Global Forecast to 2021
    “Continuous increase in vehicle sales, growing average age of existing vehicle population and growin...
    09 Dec 2016 by MarketsandMarkets USD $5,650 More Info
    Branded Generics Market: By Type (Value Added and Trade Named); By Applications: (Cardiovascular Drugs, Anti-Cancer Drugs, CNS Drugs, Anti-Infective Drugs); By Distribution (Retail Pharmacies, Hospital Pharmacies and Clinics); By Geography & Forecast – (2016 -2021)
    Branded generics drugs are similar to the innovator products but are marketed and sold under differe...
    23 Feb 2016 by USD $5,250 More Info
    Physician Views: Can Lundbeck and Otsuka's newly approved Rexulti compete with branded and generic competition in the schizophrenia and depression markets?
    ScopeFDA approval of Lundbeck and Otsuka Pharmaceuticals' Rexulti – which was announced last week – ...
    01 Jul 2015 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Branded Generics in South East Asia: Current and Future Opportunities | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types


    Buy now using our secure payment system.

    We Stock...